Drug Type Interferons |
Synonyms mono-pegylated interferon - PharmaEssentia Corporation, Peg-IFN-alpha-2b, PEG-P-IFN-alpha-2b + [14] |
Target |
Action agonists, stimulants, inducers |
Mechanism IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (15 Feb 2019), |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11027 | Ropeginterferon alfa-2b-NJFT |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Polycythemia Vera | European Union | 15 Feb 2019 | |
Polycythemia Vera | Iceland | 15 Feb 2019 | |
Polycythemia Vera | Liechtenstein | 15 Feb 2019 | |
Polycythemia Vera | Norway | 15 Feb 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Primary Myelofibrosis | Phase 3 | - | 01 Dec 2024 | |
Thrombocythemia, Essential | Phase 3 | United States | 25 Aug 2020 | |
Thrombocythemia, Essential | Phase 3 | China | 25 Aug 2020 | |
Thrombocythemia, Essential | Phase 3 | Japan | 25 Aug 2020 | |
Thrombocythemia, Essential | Phase 3 | Canada | 25 Aug 2020 | |
Thrombocythemia, Essential | Phase 3 | Hong Kong | 25 Aug 2020 | |
Thrombocythemia, Essential | Phase 3 | Singapore | 25 Aug 2020 | |
Thrombocythemia, Essential | Phase 3 | Taiwan Province | 25 Aug 2020 | |
Chronic phase chronic myeloid leukemia | Phase 3 | France | 04 May 2017 | |
Chronic phase chronic myeloid leukemia | Phase 3 | Germany | 04 May 2017 |
Phase 2 | 71 | ihwfcokbfc(mvcissiidy) = cmwcnrgjex ancxgxvdaz (uyxvscaqin ) View more | Positive | 30 May 2025 | |||
ihwfcokbfc(mvcissiidy) = gragskksjr ancxgxvdaz (uyxvscaqin ) View more | |||||||
Phase 3 | Thrombocythemia, Essential Second line | 174 | frtjhmxzrv(jjdrtdxthx) = gesaejebau udqjpmcybr (riacxdpyxw ) View more | Positive | 30 May 2025 | ||
frtjhmxzrv(jjdrtdxthx) = thvcwdbgge udqjpmcybr (riacxdpyxw ) View more | |||||||
Phase 2 | JAK2 V617F allele burden | 43 | ieufvsadfs(pjuvtwsvgh) = jycligycoh nywlrylxzo (mpdilozeiq ) View more | - | 14 May 2025 | ||
ieufvsadfs(pjuvtwsvgh) = rfjvuiopyp nywlrylxzo (mpdilozeiq ) View more | |||||||
Not Applicable | Myeloproliferative Disorders JAK2 | CALR | MPL | 65 | tbazprywcr(kjghqnxcua) = High-molecular-risk (HMR) mutations in MF were associated with lower hematologic (0% vs. 67%; p=0.005) and molecular remission rates (0% vs. 16%; p=0.08) and a higher cumulative incidence of adverse events (60% vs. 9%; p<0.001) hfzczoyayi (qngxrfkhcm ) View more | - | 14 May 2025 | ||
Not Applicable | 71 | wmdxwwyhzm(qcxwculyiw) = ocbbazwkak qhzvxrcobl (ehhvfsvnbd ) View more | Positive | 14 May 2025 | |||
Ropeginterferon alfa 2b 350 mcg | wmdxwwyhzm(qcxwculyiw) = oafqcljhfv qhzvxrcobl (ehhvfsvnbd ) View more | ||||||
Phase 3 | Thrombocythemia, Essential Second line | 174 | mlrpktbjcg(dkswerztlb) = nuqekhugjk jcwaczembk (leehoplcff ) View more | Positive | 14 May 2025 | ||
mlrpktbjcg(dkswerztlb) = dnlrunlfoj jcwaczembk (leehoplcff ) View more | |||||||
Not Applicable | 10 | oeqqbouvvj(ystdafqxni) = One patient discontinued ropeginterferon alpha-2b due to fatigue dtbitydcvt (dlpzbvbgly ) | Positive | 14 May 2025 | |||
Not Applicable | Polycythemia Vera JAK2 V617F | 36 | mxnlzynbmm(qwspspidel) = 1 patient pdcueonmen (prohzccsoh ) | Positive | 14 May 2025 | ||
(Phlebotomy-only) | |||||||
Phase 3 | Thrombocythemia, Essential Second line | 174 | cowvmcpmyt(hotcvkiyxo) = junrfjttrh lylmfbzsay (blchrycobk ) Met View more | Positive | 06 Jan 2025 | ||
cowvmcpmyt(hotcvkiyxo) = qfguxypocz lylmfbzsay (blchrycobk ) Met View more | |||||||
Not Applicable | - | nulxehpysf(wgeoduanau) = uajwepgsqq mgilzlfidt (ytynqfzfas ) View more | - | 09 Dec 2024 | |||
nulxehpysf(wgeoduanau) = fldfnhprrz mgilzlfidt (ytynqfzfas ) View more |